European Respiratory Review
Search all ERS
Interstitial Lung Diseases
Respiratory Critical Care
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
ERJ Open Research
European Lung White Book
All ERS guidelines
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
The remaining challenges of pneumococcal disease in adults
Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A.
Eur Respir Rev 2012; 21: 57-65
March 2012 - 21 (123)
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A.. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012; 21: 57-65
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
No comment yet.
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis
Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine
Source: Eur Respir J 2013; 42: 1595-1603
Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects
Source: Eur Respir J 2005; 26: 1086-1091
Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia
Source: Eur Respir J 2010; 36: 1073-1079
Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil
Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma
Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
Source: Eur Respir J 2015; 45: 1632-1641
Clinical effectiveness of pneumococcal vaccination against nonbacteremic pneumonia in people over 50 years
Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention
Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013)
Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer
Invasive pneumococcal disease (IPN) and pneumococcal vaccination in our setting
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough.
Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function
Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly
Source: Eur Respir J 2010; 36: 608-614
A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany
Source: Eur Respir J, 59 (2) 2102432; 10.1183/13993003.02432-2021
Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes
Source: Eur Respir J 2014; 43: 545-553
No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Influenza vaccination is associated with reduced severity of community-acquired pneumonia
Source: Eur Respir J 2011; 37: 147-153
Influenza and pneumococcal vaccination in patients with COPD
Source: Virtual Congress 2020 – Pharmacological management of COPD
Should pneumococcal vaccines be used to prevent LRTI?
Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new?
Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit